CYTK
VENTE TOTALE: 27 500 titres (~2 066 425,00 $ US)
- Insiders
- PARSHALL B LYNNE, Blum Robert I
- Total bought
- —
- Total sold
- $2,066,425
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-03
CYTK presents a compelling clinical catalyst with strong Phase 3 ACACIA-HCM data for aficamten published in NEJM and presented at ESC 2026, driving a high catalyst score (75) with solid confidence (0.8); however, the…
The first sentence of the analysis written for CYTK on 2026-09-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 88.5% | -1737.2% | -4284.1% | -154.6% | -127.1% | |
| Ebit Margin | -891.6% | -2722.8% | -6222.8% | -357.1% | -264.1% | |
| Ebitda Margin | -880.6% | -2671.2% | -6064.9% | -348.2% | -250.4% | |
| Operating Profit Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | |
| Pretax Profit Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | |
| Continuous Operations Profit Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | |
| Net Profit Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | |
| Bottom Line Profit Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | |
| Current Ratio | 4.529 | 6.166 | 6.117 | 9.397 | 7.454 | |
| Quick Ratio | 4.529 | 6.166 | 6.117 | 9.397 | 7.454 | |
| Solvency Ratio | -0.372 | -0.377 | -0.425 | -0.339 | -0.344 | |
| Cash Ratio | 0.605 | 0.528 | 1.101 | 0.775 | 1.568 | |
| Price To Earnings Ratio | -9.716 | -8.943 | -15.319 | -10.582 | -16.279 | |
| Price To Earnings Growth Ratio | -0.399 | 2.565 | -0.592 | -0.194 | -0.386 | |
| Forward Price To Earnings Growth Ratio | -0.399 | 2.565 | -0.592 | -0.194 | -0.386 | |
| Price To Earnings Diluted Ratio | -9.716 | -8.943 | -15.319 | -10.582 | -16.279 | |
| Price To Earnings Diluted Growth Ratio | -0.399 | 2.565 | -0.592 | -0.194 | -0.386 | |
| Price To Book Ratio | -11.562 | -38.911 | -20.860 | -38.144 | 14.371 | |
| Price To Sales Ratio | 86.624 | 285.130 | 1,070.224 | 43.513 | 49.760 | |
| Price To Free Cash Flow Ratio | -14.260 | -13.175 | -19.384 | -13.240 | -18.310 | |
| Price To Operating Cash Flow Ratio | -14.953 | -13.305 | -19.450 | -13.741 | -24.589 | |
| Debt To Assets Ratio | 0.902 | 0.563 | 0.917 | 0.739 | 0.321 | |
| Debt To Equity Ratio | -1.947 | -5.826 | -1.956 | -6.954 | 1.107 | |
| Debt To Capital Ratio | 2.056 | 1.207 | 2.046 | 1.168 | 0.525 | |
| Long Term Debt To Capital Ratio | 2.445 | 1.265 | 2.748 | 1.215 | 0.369 | |
| Financial Leverage Ratio | -2.160 | -10.354 | -2.134 | -9.405 | 3.450 | |
| Working Capital Turnover Ratio | 0.107 | 0.025 | 0.012 | 0.161 | 0.155 | |
| Operating Cash Flow Ratio | -2.519 | -2.203 | -4.035 | -3.540 | -1.983 | |
| Operating Cash Flow Sales Ratio | -5.793 | -21.430 | -55.024 | -3.167 | -2.024 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.049 | 1.010 | 1.003 | 1.038 | 1.343 | |
| Debt Service Coverage Ratio | -5.345 | -5.034 | -6.741 | -6.321 | -6.012 | |
| Interest Coverage Ratio | -5.895 | -6.199 | -8.605 | -6.338 | -6.352 | |
| Short Term Operating Cash Flow Coverage Ratio | -12.385 | -34.365 | -41.104 | -312.647 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.397 | -0.502 | -0.548 | -0.399 | -0.528 | |
| Capital Expenditure Coverage Ratio | -20.559 | -101.354 | -292.608 | -26.424 | -2.916 | |
| Dividend Paid And Capex Coverage Ratio | -20.559 | -101.354 | -292.608 | -26.424 | -2.916 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -11.335 | -12.080 | -19.054 | -14.573 | -20.765 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 88.5% | ▲1825.7% | ▲1331.4% |
| Ebit Margin | -891.6% | ▲1831.2% | ▲1200.1% |
| Ebitda Margin | -880.6% | ▲1790.6% | ▲1162.5% |
| Operating Profit Margin | -695.4% | ▲2207.3% | ▲1463.6% |
| Pretax Profit Margin | -891.6% | ▲2299.5% | ▲1466.1% |
| Continuous Operations Profit Margin | -891.6% | ▲2299.5% | ▲1466.1% |
| Net Profit Margin | -891.6% | ▲2299.5% | ▲1466.1% |
| Bottom Line Profit Margin | -891.6% | ▲2299.5% | ▲1466.1% |
| Current Ratio | 4.529 | ▼-1.637 | ▼-2.204 |
| Quick Ratio | 4.529 | ▼-1.637 | ▼-2.204 |
| Solvency Ratio | -0.372 | ▲0.005 | ▼-0.001 |
| Cash Ratio | 0.605 | ▲0.077 | ▼-0.310 |
| Price To Earnings Ratio | -9.716 | ▼-0.773 | ▲2.452 |
| Price To Earnings Growth Ratio | -0.399 | ▼-2.965 | ▼-0.598 |
| Forward Price To Earnings Growth Ratio | -0.399 | ▼-2.965 | ▼-0.598 |
| Price To Earnings Diluted Ratio | -9.716 | ▼-0.773 | ▲2.452 |
| Price To Earnings Diluted Growth Ratio | -0.399 | ▼-2.965 | ▼-0.598 |
| Price To Book Ratio | -11.562 | ▲27.350 | ▲7.460 |
| Price To Sales Ratio | 86.624 | ▼-198.506 | ▼-220.426 |
| Price To Free Cash Flow Ratio | -14.260 | ▼-1.084 | ▲1.414 |
| Price To Operating Cash Flow Ratio | -14.953 | ▼-1.648 | ▲2.255 |
| Debt To Assets Ratio | 0.901 | ▲0.339 | ▲0.213 |
| Debt To Equity Ratio | -1.947 | ▲3.879 | ▲1.168 |
| Debt To Capital Ratio | 2.056 | ▲0.849 | ▲0.656 |
| Long Term Debt To Capital Ratio | 2.445 | ▲1.180 | ▲0.837 |
| Financial Leverage Ratio | -2.160 | ▲8.195 | ▲1.961 |
| Working Capital Turnover Ratio | 0.107 | ▲0.082 | ▲0.015 |
| Operating Cash Flow Ratio | -2.519 | ▼-0.316 | ▲0.337 |
| Operating Cash Flow Sales Ratio | -5.793 | ▲15.637 | ▲11.694 |
| Free Cash Flow Operating Cash Flow Ratio | 1.049 | ▲0.039 | ▼-0.040 |
| Debt Service Coverage Ratio | -5.345 | ▼-0.311 | ▲0.546 |
| Interest Coverage Ratio | -5.895 | ▲0.304 | ▲0.783 |
| Short Term Operating Cash Flow Coverage Ratio | -12.385 | ▲21.981 | ▲67.716 |
| Operating Cash Flow Coverage Ratio | -0.397 | ▲0.105 | ▲0.078 |
| Capital Expenditure Coverage Ratio | -20.559 | ▲80.795 | ▲68.213 |
| Dividend Paid And Capex Coverage Ratio | -20.559 | ▲80.795 | ▲68.213 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -11.335 | ▲0.745 | ▲4.226 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $7.63B | $5.27B | $8.06B | $4.12B | $3.50B | |
| Enterprise value | $8.79B | $5.96B | $8.70B | $4.80B | $3.66B | |
| EV / Sales | 99.82x | 322.69x | 1155.58x | 50.75x | 51.99x | |
| EV / Op. cash flow | -17.23x | -15.06x | -21.00x | -16.03x | -25.69x | |
| EV / Free cash flow | -16.43x | -14.91x | -20.93x | -15.44x | -19.13x | |
| EV / EBITDA | -11.34x | -12.08x | -19.05x | -14.57x | -20.77x | |
| Net debt / EBITDA | -1.50x | -1.41x | -1.41x | -2.08x | -0.89x | |
| Current ratio | 4.53x | 6.17x | 6.12x | 9.40x | 7.45x | |
| Income quality | 0.65x | 0.67x | 0.79x | 0.77x | 0.66x | |
| Graham net-net | -$10 | -$4 | -$6 | -$4 | -$1 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 117.2% | 112.3% | 115.1% | 115.8% | |
| Working capital | $714.5M | $928.3M | $525.4M | $710.6M | $463.8M | |
| Invested capital | $869.7M | $1.07B | $673.1M | $873.8M | $610.2M | |
| Return on assets | -55.1% | -42.1% | -63.8% | -38.3% | -25.6% | |
| Operating ROA | -43.3% | -48.2% | -54.0% | -34.9% | -27.1% | |
| Return on tangible assets | -55.1% | -42.1% | -63.8% | -38.3% | -25.6% | |
| Return on equity | 119.0% | 435.5% | 136.2% | 360.5% | -88.3% | |
| Return on invested capital | -47.7% | -42.8% | -66.2% | -34.3% | -23.8% | |
| Return on capital employed | -50.1% | -43.9% | -68.8% | -34.9% | -24.2% | |
| Earnings yield | -10.3% | -11.2% | -6.5% | -9.5% | -6.1% | |
| Free cash flow yield | -7.0% | -7.6% | -5.2% | -7.6% | -5.5% | |
| Capex / Op. cash flow | -4.9% | -1.0% | -0.3% | -3.8% | -34.3% | |
| Capex / Depreciation | 245.0% | 41.0% | 11.9% | 195.0% | 2147.3% | |
| Capex / Sales | 28.2% | 21.1% | 18.8% | 12.0% | 69.4% | |
| SG&A / Sales | 322.9% | 1165.5% | 2305.6% | 188.2% | 137.4% | |
| R&D / Sales | 461.0% | 1837.2% | 4384.1% | 254.6% | 227.1% | |
| Stock comp / Sales | 127.5% | 529.6% | 957.0% | 50.6% | 38.1% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 74d | 329d | 62d | 1d | 269d | |
| Days payables outstanding | 805d | 22d | 24d | 39d | 48d | |
| Operating cycle | 74d | 329d | 62d | 1d | 269d | |
| Cash conversion cycle | -732d | 307d | 38d | -38d | 220d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+44.8%EV / Sales ▼-69.1%EV / EBITDA ▲+6.2%EV / Op. cash flow ▼-2.173Earnings yield ▲+0.009
Profitability
Return on equity ▼-3.165Return on assets ▼-0.130Return on invested capital ▼-0.049Return on capital employed ▼-0.062Operating ROA ▲+0.049Income quality ▼-0.022Tax burden 0.000
Efficiency
Days sales outstanding ▼-255.315Days payables outstanding ▲+783.330Operating cycle ▼-255.315Cash conversion cycle ▼-1038.645Capex / Sales ▲+0.070R&D / Sales ▼-13.762
Balance-sheet strength
Current ratio ▼-1.637Net debt / EBITDA ▼-0.093Working capital ▼-213743000.000Invested capital ▼-199543000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+117.6%EV / Sales ▲+92.0%EV / EBITDA ▲+45.4%EV / Op. cash flow ▲+8.461Earnings yield ▼-0.041
Profitability
Return on equity ▲+2.073Return on assets ▼-0.295Return on invested capital ▼-0.240Return on capital employed ▼-0.259Operating ROA ▼-0.162Income quality ▼-0.012Tax burden 0.000
Efficiency
Days sales outstanding ▼-194.909Days payables outstanding ▲+757.112Operating cycle ▼-194.909Cash conversion cycle ▼-952.021Capex / Sales ▼-0.412R&D / Sales ▲+2.340
Balance-sheet strength
Current ratio ▼-2.925Net debt / EBITDA ▼-0.607Working capital ▲+250711000.000Invested capital ▲+259475000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-06-30 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-09 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-06-17 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-06-11 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-02 Cytokinetics to Participate in September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in September: Citi 2026 BioPharma Back to School Conference: Fireside chat on Wednesday, September 9, 2026 at 3:00 PM Eastern Time in New York, NY.
- 2026-09-02 Can CYTK''s Aficamten Strengthen Its HCM Growth Prospects? Cytokinetics'' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.
- 2026-08-31 Cytokinetics Investors Weigh Safety Data From Pivotal Trial Cytokinetics Incorporated (NASDAQ:CYTK) on Friday shared primary results from the ACACIA-HCM Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
- 2026-08-29 Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across Pre-Trial Treatment Groups in Patients with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from ACACIA-HCM (Assessment Comparing A ficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) and MAPLE-HCM ( M etoprolol vs A ficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) were presented in a Late Breaking Clinical Session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany and simultaneously published in Circulation and the Journal of the American College of Cardiology: Heart Failure, respectively.
- 2026-08-28 Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript
- 2026-08-28 Cytokinetics'' Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM Cytokinetics NASDAQ: CYTK presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, or nHCM, reporting that the study met its dual primary endpoints for patient-reported health status and exercise capacity.
- 2026-08-28 Cytokinetics eyes expanded use of heart drug after promising late-stage data Cytokinetics said on Friday detailed late-stage data showed its drug, aficamten, significantly improved symptoms and exercise capacity in patients with a genetic heart condition that currently has no approved treatments.
- 2026-08-28 Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (Assessment Comparing A ficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, and simultaneously published in The New England Journal of Medicine .1 ACACIA-HCM met both dual primary endpoints, demonstrating statistically significant improvements from baseline to Week 36 compared to placebo in both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and maximal exercise performance (pVO2).
- 2026-08-22 Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 The transaction involved the disposal of 7,500 shares. The disposition resulted in a 2% reduction in the insider''s total equity holdings.
- 2026-08-20 Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy